Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma

MLA

Mohammed M. Milhem, et al. “Results of a Prospective Phase 2 Study of Pazopanib in Patients with Advanced Intermediate-Grade or High-Grade Liposarcoma.” Cancer, vol. 123, Aug. 2017, pp. 4640–47. EBSCOhost, https://doi.org/10.1002/cncr.30926.

APA

Mohammed M. Milhem, Brian L. Samuels, Pamela E. Kaiser, Sant P. Chawla, Neeta Somaiah, Mark S. Walker, Edward J. Stepanski, Keith M. Skubitz, David C. Portnoy, Arthur P. Staddon, & Dennis A. Priebat. (2017). Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer, 123, 4640–4647. https://doi.org/10.1002/cncr.30926

Chicago

Mohammed M. Milhem, Brian L. Samuels, Pamela E. Kaiser, Sant P. Chawla, Neeta Somaiah, Mark S. Walker, Edward J. Stepanski, et al. 2017. “Results of a Prospective Phase 2 Study of Pazopanib in Patients with Advanced Intermediate-Grade or High-Grade Liposarcoma.” Cancer 123 (August): 4640–47. doi:10.1002/cncr.30926.